Century Therapeutics, a preclinical biotech developing allogeneic stem cell treatments for multiple cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Century Therapeutics is developing an allogenic stem cell platform that allows it to incorporate multiple transgenes and remove target genes to optimize cell product performance. The company claims that the precision of its CRISPR-HDR gene editing technology and clonal selection eliminates random integration events and allows more controlled expression of transgenes of interest compared to other gene editing methodologies. The company expects to file an IND for its lead candidate, CNTY-101, in mid-2022, targeting CD19 for lymphoma.
The Philadelphia, PA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol IPSC. Century Therapeutics filed confidentially on March 26, 2021. J.P. Morgan, BofA Securities, SVB Leerink, and Piper Sandler are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.